|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||N/A - N/A|
|52-week range||undefined - undefined|
|Beta (3Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The Newark, California-based company said it had a loss of 33 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 19 cents per share. The results exceeded Wall Street ...
The Newark, California-based company said it had net income of 48 cents per share. Earnings, adjusted for non-recurring gains, were 28 cents per share. The results topped Wall Street expectations. The ...
President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.
Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.
In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.
Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.